KEEP BUT DO NOT DISPLAY

New Global Sugar Intake Guideline Needs Your Input See this week’s Item #1.

Researchers found participants with normal glucose tolerance but A1C rates between 5.7% and 6.4% had increased intima-media thickness and augmentation and augmentation index, suggesting that an A1C threshold of 5.7% may help better identify patients at greater cardiovascular risk. "These results suggest that an HbA1c cutoff of 5.7% is more …

In a study to determine prevalence of MHO in children, researchers found that one in three could be classified as MHO and that adiposity and lifestyle behavior may have important roles. Of the 181 children, 57 were found to be MHO-IR (31.5%), with waist circumference and dietary fat intake as …

FDA Denies Empagliflozin Approval (See this week’s Item #8.) Bydureon Pen Approved (See this week’s Item #3.)

The risk for type II endometrial cancer was not increased by any of the dietary items included in the analysis, according to the researchers. Women in the highest quintile of sugar-sweetened beverage consumption had a 78% higher risk for endometrial cancer compared with women who did not consume the beverages. …

The White House wants to add 1 more year to a provision of the Affordable Care Act that raises Medicaid reimbursement to Medicare levels for evaluation and management services, and for vaccination administration performed by primary care physicians. The act authorized this parity in Medicaid-Medicare pay for 2013 and 2014 …

Quality issues in the manufacturing plant prevents FDA from final approval. The investigational type 2 diabetes drug empagliflozin won’t win the FDA’s approval until "previously observed deficiencies" at a manufacturing plant are fixed. Eli Lilly and its partner, Boehringer Ingelheim, said the FDA had issued a complete response letter in …

Ten Year Obesity Rates Down for Young Children See this week’s summary here. More soon.

More than half of diabetes patients are at risk for developing diabetic neuropathy which in severe cases can lead to lower-extremity amputations. As a common cause of hospitalizations among diabetic patients, they drive up diabetes-related costs which totaled $245 billion in 2012, up 41% from 2007. The CDC estimates that …

A clinical study on a T1D treatment developed by Dr. Eli Lewis, a BGU researcher, in collaboration with the University of Colorado Health Science Center, had an "exceptional outcome" after an eight week treatment of the anti-inflammatory serum protein, Alpha1-Antitrypsin (AAT). "Following treatment of eight to 12 weeks with AAT, …